Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3
The experimentally established mechanism targets of Epinephrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 7/20 | 0.68 |
| ▸ | ADRB1 known ✓ | P08588 | 6/20 | 0.68 |
| ▸ | ADRB3 known ✓ | P13945 | 5/20 | 0.68 |
| ▸ | ADRA1A known ✓ | P35348 | 4/20 | 0.68 |
| ▸ | ADRA2C known ✓ | P18825 | 4/20 | 0.68 |
| ▸ | ADRA1B known ✓ | P35368 | 3/20 | 0.68 |
| ▸ | ADRA2A known ✓ | P08913 | 3/20 | 0.68 |
| ▸ | ADRA2B known ✓ | P18089 | 3/20 | 0.68 |
| ▸ | ADRA1D known ✓ | P25100 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.68 |
| ▸ | MAPT | P10636 | 7/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.68 |
| ▸ | TSHR | P16473 | 6/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.68 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.68 |
| ▸ | MEN1 | O00255 | 4/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.68 |
| ▸ | MTOR | P42345 | 3/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Racepinephrine SCHEMBL9227820 | 0.99 | KDM4E (0.69) | KDM4ETDP1MAPTADRB2HSD17B10 | |
| Racepinephrine SCHEMBL28025377 | 0.86 | KDM4E (0.93) | KDM4ETDP1MAPTADRB2HSD17B10 | |
| Phenylephrine SCHEMBL5665418 | 0.85 | HIF1A (0.73) | KDM4ETDP1MAPTADRB2HSD17B10 | |
| Oxedrine SCHEMBL6137715 | 0.85 | HIF1A (0.66) | KDM4ETDP1MAPTADRB2HSD17B10 | |
| Epinephrine SCHEMBL6536046 | 0.84 | KDM4E (0.90) | KDM4ETDP1MAPTADRB2HSD17B10 | |
| Racepinephrine SCHEMBL28217990 | 0.84 | KDM4E (0.93) | KDM4ETDP1MAPTADRB2HSD17B10 | |
| Racepinephrine SCHEMBL6536048 | 0.84 | KDM4E (0.90) | KDM4ETDP1MAPTADRB2HSD17B10 | |
| Phenylephrine SCHEMBL18305612 | 0.84 | HIF1A (0.74) | KDM4ETDP1MAPTADRB2HSD17B10 | |
| Racepinephrine SCHEMBL27805533 | 0.83 | KDM4E (0.81) | KDM4ETDP1MAPTADRB2HSD17B10 | |
| Epinephrine SCHEMBL28326081 | 0.83 | KDM4E (0.81) | KDM4ETDP1MAPTADRB2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7507258-B2 | Polymeric stent useful for the treatment of the salivary gland ducts and method for using the same | UPHEAL DENTAL LTD. (IL) | 2009-03-24 | — | — | US | claimed |
| US-11045465-B2 | Methods and compositions to prevent addiction | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| WO-2021063968-A1 | METHOD AND COMPOSITION FOR DIAGNOSING CHRONIC OBSTRUCTIVE PULMONARY DISEASE | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2021-04-08 | — | — | WO | disclosed |
| US-20200323986-A1 | HYDROPHOBIC ARENESULFONATE SALTS | THERACAINE LLC | 2020-10-15 | — | — | US | disclosed |
| US-20200323833-A1 | HYDROPHOBIC ACID ADDITION SALTS | THERACAINE LLC | 2020-10-15 | — | — | US | disclosed |
| US-20200323834-A1 | HYDROPHOBIC ACID ADDITION SALTS AND PHARMACEUTICAL FORMULATIONS THEREOF | THERACAINE LLC | 2020-10-15 | — | — | US | disclosed |
| EP-3703686-A1 | HYDROPHOBIC ARENESULFONATE SALTS | Theracaine LLC (US) | 2020-09-09 | — | — | EP | disclosed |
| EP-3704123-A1 | HYDROPHOBIC ACID ADDITION SALTS AND PHARMACEUTICAL FORMULATIONS THEREOF | Theracaine LLC (US) | 2020-09-09 | — | — | EP | disclosed |
| EP-3703696-A1 | HYDROPHOBIC ACID ADDITION SALTS | Theracaine LLC (US) | 2020-09-09 | — | — | EP | disclosed |
| US-8828432-B2 | Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles | GENERAL MILLS, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-20130289061-A1 | METHODS AND COMPOSITIONS TO PREVENT ADDICTION | THE GENERAL HOSPITAL CORPORATION | 2013-10-31 | — | — | US | disclosed |
| US-7026360-B1 | Pharmaceutical compositions containing compounds with activity for the enhancement of absorption of active ingredients | INPHARMA S.A. (CH) | 2006-04-11 | — | — | US | disclosed |
| CN-1127432-C | Valve for aerosol container | GLAXO GROUP LTD (GB) | 2003-11-12 | — | — | CN | disclosed |
| US-20020044968-A1 | High amount of plasticizer to facilitate plasticization of the matrix material at low shear and then reduced prior to adding the encapsulant to reduce post extrusion | GENERAL MILLS, INC. | 2002-04-18 | — | — | US | disclosed |
| CN-1261854-A | Valve for aerosol container | GLAXO GROUP LTD (GB) | 2000-08-02 | — | — | CN | disclosed |
| EP-0658101-B1 | SURFACTANT FREE AEROSOL FORMULATIONS CONTAINING BECLOMETHASONE DIPROPIONATE | GLAXO GROUP LTD (GB) | 1998-01-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200323833-A1 | HYDROPHOBIC ACID ADDITION SALTS | SLC26A3, SLC10A1, ABCB11 | ADRB2 1130/4885ADRB1 545/4885ADRB3 377/4885 |
| US-20200323834-A1 | HYDROPHOBIC ACID ADDITION SALTS AND PHARMACEUTICAL FORMULATIONS THEREOF | SLCO4C1, ABCB11, SLCO1B1 | ADRB2 2245/4885ADRB1 1285/4885ADRB3 748/4885 |
| US-20200323986-A1 | HYDROPHOBIC ARENESULFONATE SALTS | ARSA, SLC26A3, ABCB11 | ADRB2 554/4885ADRB1 409/4885ADRB3 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.